TABLE 1.
Baseline characteristics of each group.
| VDF-triple (N = 160) | VDA-triple (N = 160) | EBDF-quadruple (N = 160) | EBDA-quadruple (N = 160) | |
|---|---|---|---|---|
| Gender | ||||
| Male | 71 (44.38%) | 77 (48.12%) | 68 (42.50%) | 73 (45.62%) |
| Female | 89 (55.62%) | 83 (51.88%) | 92 (57.50%) | 87 (54.38%) |
| Age | 42.07 ± 13.06 | 41.60 ± 14.89 | 42.44 ± 14.37 | 40.38 ± 13.54 |
| Gastroscopy result | ||||
| Peptic ulcer | 31 (19.38%) | 32 (20.00%) | 25 (15.62%) | 34 (21.25%) |
| Chronic non-atrophic gastritis | 27 (16.87%) | 20 (12.50%) | 31 (19.38%) | 25 (15.63%) |
| Reflux gastritis | 7 (4.37%) | 13 (8.12%) | 6 (3.75%) | 5 (3.12%) |
| Atrophic gastritis | 16 (10.00%) | 23 (14.38%) | 26 (16.25%) | 20 (12.50%) |
| Lack of gastroscopy | 79 (49.38%) | 72 (45.00%) | 72 (45.00%) | 76 (47.50%) |
| Take extra medicine | ||||
| Yes | 22 (13.75%) | 31 (19.37%) | 28 (17.50%) | 27 (16.87%) |
| No | 138 (86.25%) | 129 (80.63%) | 132 (82.50%) | 133 (83.13%) |
Note: VDF-triple, VPZ + Furazolidone + Doxycycline; VDA-triple, VPZ + Amoxicillin + Doxycycline; EBDF-quadruple, EPZ + Colloidal bismuth tartrate + Furazolidone + Doxycycline; EBDA-quadruple, EPZ + Colloidal bismuth tartrate + Amoxicillin + Doxycycline.